ReviewTouchREVIEWS in endocrinology2026
The CKD-OSTEO Score: A Chronic Kidney Disease-specific Tool for Osteoporosis Risk Stratification.
Review in TouchREVIEWS in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis in patients with chronic kidney disease (CKD) frequently goes undiagnosed and is not treated adequately, largely due to its intricate pathophysiology and the lack of risk stratification tools specific to CKD. Standard tools used for the general populace, such as the Fracture Risk Assessment Tool (FRAX) score and bone mineral density-based thresholds, fail to accurately represent the unique biochemical and structural bone alterations that take place in CKD stages IIIb-VD. We propose the Chronic Kidney Disease Osteoporosis Stratification Tool for Evaluation and Optimization (CKD-OSTEO) score, an innovative multidimensional clinical tool intended to evaluate the risk of osteoporosis, direct diagnostic assessments and inform suitable treatment strategies for patients with CKD. This score integrates conventional fracture risk factors with CKD-specific components, such as dialysis vintage, intact parathormone levels, serum Klotho levels and T-scores. We explain the pathophysiological rationale for each element, categorize patients into various management levels and provide customized recommendations for starting and selecting anti-resorptive therapy. Emphasis is placed on the growing importance of Klotho deficiency as a marker of bone-vascular ageing. With this article, we advocate for the regular risk stratification of patients with CKD to enhance fracture prevention, tailor treatment strategies and incorporate new biomarkers like Klotho into practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.